BeiGene

We believe in leading with science to drive innovation. Our dedicated research team is delivering one of the largest and most compelling #oncology pipelines in the industry, uniting cutting-edge science with global development scale to advance tomorrow’s #cancer medicines.     Learn more about our approach to cancer biology and areas of innovation at https://bit.ly/3RE0Bs1. 

We believe in advancing inclusiveness in research and clinical trials and developing innovative treatments that address the unique needs of all patients. We partner with diverse patient communities early in the process and aim to deliver therapies that are safe and effective for more people living with #cancer.     Join us in celebrating Disability Pride Month by promoting awareness, fostering inclusivity, and recognizing the significant contributions of individuals with disabilities in our communities. Together, we can create a more equitable future for all.     Learn more about our commitment to global health equity at https://lnkd.in/eB6fpQjz.     #DisabilityPrideMonth #HealthEquity 

The impact of #cancer extends far beyond the biology of the disease. In recognition of National Minority Mental Health Awareness Month and throughout the year, we advocate for equitable #MentalHealth resources for all, including all cancer patients. Our dedication to global #HealthEquity involves addressing health disparities and bringing awareness to the unique challenges that racial and ethnic minorities face when it comes to mental illness. Learn more about our commitment to making mental health and emotional wellness an integral part of quality cancer care for all patients, their families and care partners at https://bit.ly/3VS5H6r. #TalkAboutIt #NationalMinorityMentalHealthAwarenessMonth

By 2030, ~14% of the population in Southeast Asia will be 60 or older, rising to 20% by 2050. This aging trend is expected to lead to an increase in chronic diseases, including #cancer, and a greater demand for long-term care. However, health systems in the region are often ill-equipped to manage these challenges, which disproportionately affects disadvantaged vulnerable populations and worsen health inequities. While innovations in medicines are critical, so are the advances in educating and training the #healthcare workforce, which can directly improve access and equity in care. The latest Asia Society report, supported by BeiGene, uses Thailand as a case study to demonstrate the importance of healthcare workforce education in improving cancer control across the region. Read the full report here: https://bit.ly/3RR9MVP.

We believe in leading with science to make transformative medicines a reality. We collaborate globally, using cutting-edge science and technology to change how cancer is treated for good. To do this we are advancing a deep pipeline of investigational medicines, and we are innovating with urgency to bring our impactful therapies to more patients around the world. Learn more about our approach to research and development at https://bit.ly/3Xt2Zp6. #BeiGene #believe #cancer

In a recent interview with SurvivorNet, our Chief Commercial Officer for North America & Europe, Josh Neiman, emphasized the importance of addressing the unmet #MentalHealth needs of patients with #cancer. He encouraged all who work in the field to be sincere, honest, and hopeful when sharing information with people dealing with cancer. At BeiGene, we’re committed to ensuring those facing cancer receive not only innovative treatments but also the knowledge and support they need during their journey. Our ‘Talk About It’ program provides mental health resources to help patients and their loved ones feel heard, and to help navigate the challenges they face that are beyond physical. Watch the interview here: https://bit.ly/3zma0y2.

#News for #Investors and #Media: This week’s #ESMOGI2024, taking place in Munich, Germany, is an opportunity for BeiGene colleagues to convene with oncologists from around the world to share the latest science in gastrointestinal cancers. We’re proud to be presenting important new data from two of our Phase 3 studies in esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer. #ESCC #GEJC

Our investigational BCL2 inhibitor was recently granted Fast Track Designation by the FDA for relapsed/refractory Waldenström macroglobulinemia (#WM), recognizing the potential for this next-generation compound to address significant unmet need. Read more about WM and how we are leading with science to advance innovative #oncology medicines for patients: https://bit.ly/3x2LVeW

#PrideMonth is a time to honor the history and achievements of the LGBTQIA community and raise awareness of the ongoing struggles its members are facing.   This month we hosted an internal discussion on supporting the LGBTQIA community and addressing its members’ #healthcare challenges. Our colleagues also participated in a virtual volunteer event with Micro Rainbow, OUTMemphis and Benevity, learning tips and tools to foster meaningful conversations about inclusion and become an everyday ambassador for love and acceptance.   We’re committed to promoting inclusivity, diversity and equity, as these values drive innovation and collaboration, leading to better outcomes for our patients. Learn more at https://bit.ly/3KbrNtS.

As part of our commitment to delivering innovative medicines that address significant unmet needs to more patients around the world, we’ve built one of the most prolific #oncology pipelines in the industry, addressing 80% of the world’s #cancers. Hear from our Co-Founder, Chairman and CEO John Oyler discussing the many exciting assets in our pipeline in this interview with BiotechTV.